Assaf Hanan A, Ahmed Dina, Abdelhamed Amr
Dermatology, Venereology and Andrology Department, Faculty of Medicine, Sohag University, Sohag, Egypt.
Indian J Dermatol. 2022 Sep-Oct;67(5):504-511. doi: 10.4103/ijd.ijd_394_21.
Periorbital hyperpigmentation (POH) is a common skin condition that presents as infraorbital darkening. POH has a multifactorial etiology. Studies evaluating POH treatment are several with varying satisfaction results.
To compare carboxytherapy and microneedling (MN) combined with topical glutathione for POH treatment.
A split-face pilot clinical trial was conducted on 31 female patients with POH. Carboxytherapy injection was done at the right periorbital area, and MN with topical glutathione (Left periorbital area), for 6 biweekly sessions. Visual analogue scale (VAS), dermoscopic evaluation, patient satisfaction, and patient dermatology life quality index questionnaire (DLQI), safety evaluation were done with 3 months follow up. The trial registry number is NCT04389788.
Carboxytherapy showed a higher significant improvement as regards VAS evaluation compared to MN with glutathione during the active treatment phase ( = 0.001) and during the follow-up phase ( = 0.006). Also, the dermoscopic evaluation showed a statistically significant improvement in the Carboxytherapy group. DLQI showed a statistically significant improvement ( <.001). As regards patient satisfaction, carboxytherapy showed in comparison to MN with glutathione (80.6% vs 25.8% in moderate satisfaction) and (3.2% vs 0% in marked satisfaction respectively) ( = .05). As regards the patients' safety, there was no significant difference between both eyes ( = .23).
Carboxytherapy showed higher efficacy than MN with glutathione in POH patients. Carboxytherapy improved clinical, dermoscopic, patient satisfaction, and patient DLQI; with a good safety profile.
眶周色素沉着(POH)是一种常见的皮肤状况,表现为眶下皮肤变黑。POH的病因是多因素的。评估POH治疗方法的研究有很多,但满意度结果各不相同。
比较羧基疗法与微针(MN)联合外用谷胱甘肽治疗POH的效果。
对31例患有POH的女性患者进行了一项半脸试点临床试验。在右侧眶周区域进行羧基疗法注射,在左侧眶周区域进行MN联合外用谷胱甘肽治疗,每两周进行6次治疗。在3个月的随访中,采用视觉模拟量表(VAS)、皮肤镜评估、患者满意度以及患者皮肤病生活质量指数问卷(DLQI)进行评估,并进行安全性评估。试验注册号为NCT04389788。
在积极治疗阶段(P = 0.001)和随访阶段(P = 0.006),与MN联合谷胱甘肽相比,羧基疗法在VAS评估方面显示出更高的显著改善。此外,皮肤镜评估显示羧基疗法组有统计学意义的改善。DLQI显示有统计学意义的改善(P <.001)。在患者满意度方面,与MN联合谷胱甘肽相比,羧基疗法表现更好(中度满意度分别为80.6%对25.8%)和(显著满意度分别为3.2%对0%)(P =.05)。在患者安全性方面,双眼之间没有显著差异(P =.23)。
在POH患者中,羧基疗法比MN联合谷胱甘肽显示出更高的疗效。羧基疗法改善了临床、皮肤镜检查、患者满意度和患者DLQI;且安全性良好。